EMA Authorised: Bortezomib Accord (bortezomib) — Accord Healthcare S.L.U.

View source ↗

Summary

EMA authorised Bortezomib Accord for the treatment of multiple myeloma; the product is marketed by Accord Healthcare S.L.U. with a decision dated 24 March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib Accord (bortezomib)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Accord Healthcare S.L.U.. Decision date: 24/03/2026